Machine Learning-Based Nomogram for Predicting Overall Survival in Elderly Patients with Cirrhotic Hepatocellular Carcinoma Undergoing Ablation Therapy
Wenying Qiao,Shugui Sheng,Junnan Li,Ronghua Jin,Caixia Hu
DOI: https://doi.org/10.2147/jhc.s450825
2024-03-07
Journal of Hepatocellular Carcinoma
Abstract:Wenying Qiao, 1– 5, &ast Shugui Sheng, 1– 3, &ast Junnan Li, 1– 3, &ast Ronghua Jin, 1– 4 Caixia Hu 5 1 Beijing Key Laboratory of Emerging Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China; 2 Beijing Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China; 3 National Center for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China; 4 Changping Laboratory, Beijing, People's Republic of China; 5 Interventional Therapy Center for Oncology, Beijing You'an Hospital, Capital Medical University, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Ronghua Jin, Beijing Key Laboratory of Emerging Infectious Diseases, BeijingDitan Hospital, Capital Medical University, Beijing, People's Republic of China, Email Caixia Hu, Interventional Therapy Center for Oncology, Beijing You'an Hospital, Capital Medical University, Beijing, People's Republic of China, Email Purpose: The aim of the study is to identify and evaluate multifaceted factors impacting the survival of elderly cirrhotic HCC patients following ablation therapy, with the goal of constructing a nomogram to predict their 3-, 5-, and 8-year overall survival (OS). Patients and Methods: A retrospective analysis was conducted on 736 elderly cirrhotic HCC patients who underwent ablation therapy between 2014 and 2022. LASSO regression, random survival forest (RSF), and multivariate Cox analyses were employed to identify independent prognostic factors for OS, followed by the development and validation of a predictive nomogram. Harrell's concordance index (C-index), calibration plot and decision curve analysis (DCA) were used to assess the performance of the nomogram. The nomogram was finally utilized to stratify patients into low-, intermediate-, and high-risk groups, aiming to assess its efficacy in precisely discerning individuals with diverse overall survival outcomes. Results: Alcohol drinking, tumor number, globulin (Glob) and prealbumin (Palb) were identified and integrated to establish a novel prognostic nomogram. The nomogram exhibited strong discriminative ability with C-indices of 0.723 (training cohort) and 0.693 (validation cohort), along with significant Area Under the Curve (AUC) values for 3-year, 5-year, and 8-year OS in both cohorts (0.758, 0.770, and 0.811 for training cohort; 0.744, 0.699 and 0.737 for validation cohort). Calibration plots substantiated its consistency, while DCA curves corroborated its clinical utility. The nomogram further demonstrated exceptional effectiveness in discerning distinct risk populations, highlighting its robust applicability for prognostic stratification. Conclusion: Our study successfully developed and validated a robust nomogram model based on four key clinical parameters for predicting 3-, 5- and 8-year OS among elderly cirrhotic HCC patients following ablation therapy. The nomogram exhibited a remarkable capability in identifying high-risk patients, furnishing clinicians with invaluable insights for postoperative surveillance and tailored therapeutic interventions. Keywords: hepatocellular carcinoma, HCC, nomogram, LASSO regression, random survival forest, RSF, overall survival, OS Liver cancer poses a significant challenge to global health, occupying the sixth position in terms of its incidence and ranking third in mortality rates. 1 Hepatocellular carcinoma (HCC) is the predominant type of liver cancer, comprising 75–85% of all cases. 2 With the advent of an aging society, the increasing prevalence of HCC with cirrhosis among elderly individuals has garnered extensive attention. 3,4 Surgical resection is indeed the most common method used for the treatment of HCC, particularly in cases where the tumor is localized and the patient's liver function is adequate. Treatment options for HCC also include transarterial chemoembolization (TACE), radiation therapy, chemotherapy, targeted therapy, and immunotherapy. Over recent years, there has been a gradual rise in the proportion of HCC patients opting for ablation therapy. 5–7 Elderly patients with cirrhotic HCC often face challenges in tolerating more invasive treatments like surgery or liver transplantation due to age-related ailments and reduced physiological reserves. Ablation therapy offers a less invasive alternative for this population. It reduces surgical burden, preserves liver function, lowers complication risks, shortens recovery, and provides repeatable -Abstract Truncated-
oncology